It will be interesting, given the recent announcements concerning the human genome, to see how the market reacts. |
It will be really interesting to see how the momentum plays out for both stocks the next few days. |
It's a fairly large issue but the semiconductor sector continues to be really strong. It wouldn't surprise me if they increase the range going forward. |
It's a totally different kind of deal. It's not a high-tech company and that's kind of a good thing. |
It's too early for a rebound though, and the market is still very selective. |
It's troubling in the long term because we saw the number of filings decrease in second quarter versus first quarter. |
It's very interesting to see a deal double in a really slow week like this. Because they produce components for high-growth segments of the market, this may have excited investors. |
Just because of Andreessen, this will get institutions interested. |
Martha Stewart has been doing this for a long time. I don't think it's a fad. |
Odyssey is in wait-and-see mode. It's kind of unknown what the institutional demand will be. |
Rigel is coming out at the worst possible time. |
Semiconductors are not what the market wants to see right now. |
Since we're coming out of a gap, we would like to see the deals stick with their price ranges. This would show they didn't lower their terms to get the institutions to bite. |
Support.com offers a one-stop shop, which is appealing. |
Technology had a reasonably good run on the Nasdaq last weekend, but once again it's really wait and see how they price. |